BOSTON and LONDON – October 3, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Press Release
Akari Therapeutics’ Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate …
Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer
BOSTON and LONDON – September 17, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BOSTON and LONDON – September 5, 2025 – Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug …
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON – September 3, 2025 – Akari Therapeutics, Plc …
[Read more...] about Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
